Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.210
+0.060 (1.45%)
At close: Mar 6, 2026
-43.84%
Market Cap 258.28M
Revenue (ttm) n/a
Net Income (ttm) -113.26M
Shares Out 61.35M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50,475
Average Volume 33,414
Open 4.100
Previous Close 4.150
Day's Range 4.100 - 4.225
52-Week Range 4.010 - 10.980
Beta 0.70
RSI 33.68
Earnings Date Feb 11, 2026

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 20
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.